All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Michael DickinsonDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson, Peter MacCallum Cancer Center, Melbourne, AU, about a study investigating the combination of RG6146, venetoclax and rituximab in patients with relapsed/refractory DLBCL.
Michael Dickinson mentioned how rituximab was added to the combination once the dose of venetoclax and RG6146 was established. Results showed an overall response rate of 45%, and a complete remission rate of 24%.
RG6146 and venetoclax in DLBCL